Edition:
India

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

4.49USD
9:36pm IST
Change (% chg)

$-0.09 (-1.86%)
Prev Close
$4.57
Open
$4.56
Day's High
$4.57
Day's Low
$4.46
Volume
41,516
Avg. Vol
340,329
52-wk High
$11.60
52-wk Low
$4.09

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics Says Anticipates Delayed Filing Of Annual Report On Form 10-K
Tuesday, 19 Mar 2019 

March 18 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES PRELIMINARY FULL-YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKEBIA THERAPEUTICS INC - ENDED 2018 WITH CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES OF $321.6 MILLION.AKEBIA - SEES CASH RESOURCES, INCLUDING PREPAID QTRLY COMMITTED COST-SHARE COLLABORATION PARTNER FUNDING, TO FUND CURRENT OPERATING PLAN INTO Q3 2020.AKEBIA THERAPEUTICS - ANTICIPATES DELAYED FILING OF ANNUAL REPORT ON FORM 10-K FOR FISCAL YEAR ENDED DEC 31, 2018.AKEBIA THERAPEUTICS INC QTRLY PRELIMINARY COLLABORATION REVENUES $53.0 MILLION VERSUS $90.6 MILLION.AKEBIA THERAPEUTICS INC - NO REVENUE WAS RECOGNIZED UNDER MTPC COLLABORATION AGREEMENT IN Q4 OF 2018.AKEBIA THERAPEUTICS INC QTRLY PRELIMINARY PRE-TAX NET LOSS OF $88.4 MILLION VERSUS PRE-TAX NET INCOME OF $15.5 MILLION.  Full Article

Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA DUE TO CHRONIC KIDNEY DISEASE.EACH STUDY, ONE IN NON-DIALYSIS DEPENDENT SUBJECTS AND ONE IN HEMODIALYSIS-DEPENDENT SUBJECTS, MET ITS PRIMARY ENDPOINT.MITSUBISHI TANABE PHARMA CORPORATION EXPECTS TO SUBMIT A JAPANESE NEW DRUG APPLICATION IN 2019.  Full Article

Nantahala Capital Management, Llc Reports 4.7 pct Stake In Akebia Therapeutics As Of Dec 12
Saturday, 22 Dec 2018 

Dec 21 (Reuters) - :NANTAHALA CAPITAL MANAGEMENT, LLC REPORTS 4.7 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF DEC 12, 2018 - SEC FILING.NANTAHALA CAPITAL MANAGEMENT, LLC - HAD PREVIOSULY REPORTED 9.8 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF SEPT 25, 2018.  Full Article

Keryx Signs Letter Of Intent with Akebia Therapeutics Related To Auryxia
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Keryx Biopharmaceuticals ::ON OCT 24, ENTERED LETTER AGREEMENT WITH PANION & BF BIOTECH, AND AKEBIA THERAPEUTICS RELATED TO AURYXIA - SEC FILING.PANION AGREED TO RESCIND ANY AND ALL PRIOR TERMINATION THREATS OR NOTICES RELATING TO LICENSE AGREEMENT.PANION WAIVED ITS RIGHTS TO TERMINATE LICENSE AGREEMENT BASED ON ANY BREACH BY KERYX OF CERTAIN OBLIGATION.TERMS INCLUDE ESTABLISHING A JOINT STEERING COMMITTEE WITH PANION, AKEBIA REPRESENTATIVES RELATED TO FEXERIC IN EUROPE.  Full Article

Akebia Therapeutics Says Co Entered First Amendment To Agreement & Plan Of Merger With Alpha Therapeutics, Co's Unit And Keryx
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS SAYS CO ENTERED FIRST AMENDMENT TO AGREEMENT & PLAN OF MERGER WITH ALPHA THERAPEUTICS, CO'S UNIT AND KERYX - SEC FILING.AKEBIA THERAPEUTICS - FIRST AMENDMENT PROVIDES AT MERGER CO MUST CAUSE INCREASE IN SIZE OF THE AKEBIA BOARD TO 10 DIRECTORS.AKEBIA THERAPEUTICS - FIRST AMENDMENT PROVIDES AT MERGER ADDITIONAL DIRECTOR SHALL SERVE AS CHAIRPERSON OF AKEBIA BOARD.  Full Article

Nantahala Capital Management Reports 9.8 Pct Stake In Akebia Therapeutics
Thursday, 27 Sep 2018 

Sept 26 (Reuters) - Nantahala Capital Management Llc::NANTAHALA CAPITAL MANAGEMENT LLC REPORTS 9.8 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF SEPTEMBER 25 - SEC FILING.NANTAHALA CAPITAL MANAGEMENT LLC PURCHASED AKEBIA THERAPEUTICS COMMON STOCK BASED ON BELIEF THAT COMMON STOCK, WHEN PURCHASED, WAS UNDERVALUED.  Full Article

Akebia Therapeutics Q2 Loss Per Share $0.60
Thursday, 9 Aug 2018 

Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.60.Q2 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S.QUARTERLY COLLABORATION REVENUE $48.8 MILLION VERSUS $28.5 MILLION.  Full Article

Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA ASSOCIATED WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE.DATA CONSISTENT WITH FINDINGS FROM PREVIOUS STUDIES​.‍PHASE 3 STUDY OF NON-DIALYSIS PATIENTS IN JAPAN ONGOING; PHASE 3 STUDIES OF DIALYSIS PATIENTS TO BEGIN IN 2018​.STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT OBSERVED IN VADADUSTAT GROUP 150 MG (P = 0.0004) COMPARED TO PLACEBO​.STATISTICALLY SIGNIFICANT IMPROVEMENTS ALSO OBSERVED IN VADADUSTAT GROUPS 300 MG(P<0.0001), 600 MG(P< 0.0001),COMPARED TO PLACEBO​.SERIOUS ADVERSE EVENTS WERE CONSISTENT WITH PRIOR STUDIES.NO DEATHS WERE REPORTED.  Full Article

Akebia Therapeutics reports Q3 loss per share $0.49
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.49.Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc -cash, cash equivalents and available for sale securities $329.7 million at sept 30 versus $260.3 million as at dec 31, 2016​.  Full Article